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Antifi brinolytic Therapy in Complex Spine 
Surgery. A Case-Control Study Comparing 
Aprotinin and Tranexamic Acid.
MARIA J. COLOMINA, MD; JOAN BAGÓ, MD; XAVI VIDAL, MD; LIDIA MORA, MD; FERRAN PELLISÉ, MD
A case-control study was performed to determine the impact of aprotinin or tranexamic 
acid use on reducing intraoperative blood loss and transfusion needs in complex spine 
surgery. Sixty-nine patients undergoing complex spine surgery received aprotinin or 
tranexamic acid. The aprotinin group contained 30 patients (8 men and 22 women) 
and the tranexamic acid group 39 patients (11 men and 28 women). The following 
variables were recorded: duration of surgery, number of levels fused, intraoperative 
and total blood loss, and number of blood units transfused (autologous and allogenic). 
In addition, various parameters related to blood loss in this type of surgery were cal-
culated. The groups differed with regard to duration of surgery (aprotinin 662 min 
vs tranexamic acid 448 min, P.001) and number of levels fused (aprotinin 11.2 vs 
tranexamic acid 7.6, P.004). There were no signifi cant differences in intraoperative 
blood loss (aprotinin 2118 mL vs tranexamic acid 1608 mL, P.066) or total blood 
loss (aprotinin 3312 mL vs tranexamic acid 2627 mL, P.056). Statistical differences 
were found for the number of autologous blood units transfused (aprotinin 2.2 vs 
tranexamic acid 1.3 P.047) and total units transfused (aprotinin 4.1 vs tranexamic 
acid 2.6, P.008). Blood loss per hour of surgery, transfused units per level fused and 
transfused units per hour of surgery were similar in the 2 groups. Signifi cant differ-
ences were found for intraoperative blood loss per fusion level (aprotinin 228 mL vs 
tranexamic acid 428, P.025) and total blood loss per fusion level (aprotinin 360 mL 
vs tranexamic acid 638 mL, P.01). Analysis of the applied geometric mean showed 
that aprotinin reduced total blood loss by 16.4% and total number of blood units trans-
fused by 12.4% as compared to tranexamic acid, although statistical signifi cance was 
not reached. The type of antifi brinolytic used did not have a signifi cant impact on the 
main outcome variables of the study. 
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Complex spine surgery is associated with a considerable loss of blood during the procedure.1-3 This is a 
result of several characteristics inherent 
to the surgery, such as extensive bone de-
cortication, the release of particles during 
bone manipulation (eg, thromboplastin), 
fl uid therapy-induced dilutional coagu-
lopathy, and the microthrombi present in 
transfusion blood.1,4-6 Much concern has 
focussed on avoiding blood transfusion in 
this type of surgery and several measures 
have been adopted to achieve this. Among 
them, the use of antifi brinolytic drugs may 
be effective.7-10
Antifi brinolytic agents have been 
mainly used in heart surgery to reduce in-
traoperative bleeding and transfusion re-
quirements.11 In addition, they have been 
introduced in several major orthopedic 
surgical procedures. Two recent meta-
analyses by Shiga et al12 and Zufferey et 
al13 have confi rmed the effi cacy of apro-
tinin and tranexamic acid versus placebo 
on intraoperative blood loss and transfu-
sion needs in various orthopedic surgery 
procedures. A Cochrane Collaboration 
Review14 has gathered evidence that Apro-
tinin and tranexamic acid reduce periop-
erative transfusion needs and decrease 
intraoperative blood loss in both heart sur-
gery and orthopedic surgery. The review 
recommended that comparative studies 
between these 2 agents be performed to 
determine whether there are signifi cant 
differences in their performance, instead 
of new placebo-controlled studies. Nev-
ertheless, no published articles with these 
characteristics have emerged and there are 
no comparative studies on the use of these 
drugs in spine surgery.
This study evaluated the effectiveness 
of aprotinin and tranexamic acid in the 
management of intraoperative blood loss 
and transfusion requirements in patients 
undergoing complex surgery of the spine.
MATERIAL AND METHODS
This is a retrospective study of 2 series 
of patients scheduled for complex spine 
surgery who received different antifi bri-
nolytics during surgery. From 2001 to 
2003 intraoperative antifi brinolytic agents 
were used in 69 cases. The patients for 
whom this treatment was decided were 10 
to 75 years, with a body weight 30 kg 
and a body mass index 30 kg/m2, sched-
uled for complex spine surgery. Patients 
with spinal tumors or acute trauma often 
receive antifi brinolytic treatment as well, 
but were not included in the analysis. The 
use of antifi brinolytics was not consid-
ered indicated in patients with a history 
of allergy or hypersensitivity to the agents 
used, those under treatment with drugs 
that might interfere with coagulation  (eg, 
acetylsalicylic acid, nonsteroid anti-in-
fl ammatory drugs, and anticoagulants), 
history of frequent bleeding, platelet count 
150,000/mm3, abnormal prothrombin 
time or activated partial thromboplastin 
time, a history of a thromboembolic epi-
sode or family history of thromboembo-
lism, or plasma creatinine values 1.3 
mg/dL.
Groups
The antifi brinolytic drugs under study 
were aprotinin and tranexamic acid. The 
decision of which of these drugs to use 
was made by the attending anesthesiolo-
gist. 
Tranexamic Acid Group. The 
tranexamic acid group was comprised of 
39 patients (28 women and 11 men) with 
a mean age of 35.1 years (SD 18.2). The 
diagnoses included adult scoliosis in 16 
patients, neuromuscular scoliosis in 7, 
congenital scoliosis in 1, and degenerative 
lumbosacral disease in 15. The surgical 
interventions were posterior instrumented 
fusion in 28 patients, anterior instrument-
ed fusion in 1, and anterior plus posterior 
instrumented fusion in 10. In 12 cases, 
360º fusion was performed using a pos-
terior lumbar interbody approach (PLIF): 
one-level PLIF in 7 cases, two-level PLIF 
in 4, and three-level PLIF in 1. In 2 ad-
ditional cases, extensive laminectomy was 
done to treat severe central stenosis (one-
level decompression in 1 case and two-
level decompression in another patient). 
Tranexamic acid (Amchafi brin 500 mg; 
Rottapharm S.L., 5-mL vials) was admin-
istered at a bolus dose of 10 mg/kg during 
20 minutes before starting surgery, and at 
2 mg/kg/hour in continuous perfusion up 
to completion of the procedure. 
Aprotinin Group. The aprotinin group 
contained 30 patients (22 women and 
8 men) with a mean age of 41.4 years 
(SD 17.0). The diagnoses included adult 
scoliosis in 17 patients, neuromuscular 
scoliosis in 8, degenerative lumbosacral 
disease in 2, and posttraumatic kyphosis 
in 3. The surgical intervention consisted 
of posterior instrumented fusion in 8 pa-
tients and anterior plus posterior instru-
mented fusion in 22 patients. To correct 
sagittal plane imbalance, pedicle subtrac-
tion osteotomy at L3 was done in one case 
and multiple Smith-Petersen osteotomies 
in another case. One patient received a 
two-level PLIF, four-level canal steno-
sis decompression was done in another 
patient, and one-level decompression in 
another. Aprotinin (Trasylol; Bayer AG, 
50-mL vials, 70 mg of aprotinin, equiva-
lent to 500,000 kallikrein inhibiting units 
[KIU]) and sodium chloride 0.9% as iso-
tonic solution was administered as a bolus 
dose of 240 mg/m2 (approximately 2.106 
KIU) during 20 minutes at 30 minutes 
before the fi rst surgical incision and fol-
lowing administration of a recommended 
test dose of 5000 KIU (1 mL of the so-
lution). After administration of the initial 
bolus, continuous perfusion at 56 mg/m2 
(approximately 500,000 KIU/hour) was 
given to completion of surgery. 
The anesthesia technique included 
propofol, fentanyl, midazolam, and ro-
curonium bromide in all cases. Mechani-
cal ventilation was set at a minute-volume 
equivalent to 10 mL/kg and a respiratory 
rate of 10 to 12 breaths per minute. We 
used 100% oxygen for preoxigenation 
and 50% oxygen for the remainder of the 
intervention. Maintenance anesthesia con-
sisted of continuous perfusion of fentanyl 
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at 3-5 g/kg/hour, rocuronium bromide 
at 0.02 mg/kg/hour, and desfl urane as the 
hypnotic agent.
Various parameters that might have 
an infl uence on intraoperative blood loss 
were controlled during surgery. Patients 
were maintained at an esophageal tem-
perature of >35 C, mean blood pressure 
55 to 70 mm Hg, PaCO2 34 to 40 mm Hg, 
and fl uid support to maintain the urinary 
output at 0.5 mL/kg/hour. Following 
surgery, all patients were monitored for 
at least 24 hours in the recovery unit and 
were attended by the same surgery-anes-
thesia team up to hospital discharge. 
The following variables were recorded 
for each patient: 1) anthropometric char-
acteristics, including weight, height, and 
body mass index (BMI); 2) surgery char-
acteristics, including duration of the pro-
cedure, number of levels fused, and days 
hospitalized; 3) intraoperative blood loss, 
measured by aspiration and by weighing 
the sponges and gauze used on a digital 
scale; 4) postoperative blood loss, mea-
sured as the volume through the drains 
during the fi rst 48 hours. Total blood loss 
was calculated as the sum of the intraop-
erative loss plus the postoperative loss at 
48 hours following surgery; (5) number 
of units of predonated autologous blood 
and allogenic blood transfused. The trans-
fusion trigger was established at 8 g/dL. 
The following were also monitored: pro-
thrombin time (PT), activated partial 
thromboplastin time (APTT), fi brinogen, 
and platelets. Administration of fresh-
frozen plasma was indicated when the 
international normalized ratio (INR) was 
1.5, fi brinogen 0.5 g/dL, and platelets 
80.000/mm3, and whenever there was 
clinical evidence of bleeding; and 6) ad-
verse effects (thrombotic phenomena and 
allergic reactions) associated with use of 
the drugs.
Since it is known that perioperative 
blood loss is related with the character-
istics of the surgery (duration and levels 
fused),1,15,16 the following parameters 
were calculated to facilitate the between-
group comparisons: intraoperative blood 
loss per level fused and total blood loss 
per level fused (mL/level), intraoperative 
blood loss per hour of surgery (mL/h), 
transfused units per level fused and per 
hour of surgery.
Statistical Analysis
The statistical analysis was carried out 
with SAS, version 9.1. A descriptive anal-
ysis of the main variables was performed 
in the two groups. The comparison of 
means was done with Student’s t test 
and comparison of percentages with chi-
square analysis. To compare the results of 
the variable total blood loss, values were 
fi rst submitted to logarithmic transforma-
tion to normalize the distribution. Subse-
quently, multivariate regression analysis 
was done using total blood loss as the 
dependent variable and the following as 
predictive variables: age, sex, duration of 
surgery, number of fused levels, baseline 
hemoglobin and hematocrit, and the type 
of drug received. A second multivariate 
analysis was performed using total num-
ber of units transfused as the dependent 
variable.  
RESULTS
There were no signifi cant differences 
between the groups with regard to age 
(aprotinin 41.4 vs tranexamic acid 35.1), 
weight (aprotinin 60.9 kg vs tranexamic 
acid 61.8 kg), height (aprotinin 157 cm vs. 
tranexamic acid 160 cm), or BMI (apro-
tinin 24.70 vs tranexamic acid 24.14). 
The data related to the surgical interven-
tion are shown in Table 1. In the aprotinin 
group, values were signifi cantly higher for 
the duration of surgery (P.001) and the 
number of fused levels (P.004). There 
were no differences in the duration of hos-
pitalization.
Baseline hemoglobin and hematocrit 
were similar in the 2 groups (Table 2). 
There were no signifi cant differences in the 
intraoperative, postoperative or total blood 
loss, although it should be noted that total 
blood loss in the aprotinin group was al-
most 700 mL greater than in the tranexam-
ic acid group. Intraoperative blood loss in 
the aprotinin group was almost 700 mL 
greater than in the tranexamic acid group. 
Intraopertaive blood loss relative to blood 
volume of each patient was 0.42 (42%) in 
the tranexamic acid group and 0.55 (55%) 
in the aprotinin group. A larger (although 
nonsignifi cant) difference was observed 
when total blood loss was calculated ac-
cording to blodd volume: tranexamic 
acid group 0.69 and aprotinin group 1.46. 
Postoperative hemoglobin and hematocrit 
were similar in both groups. 
Table 3 depicts the transfusion re-
quirements in the two groups. Aprotinin 
patients received more autologous blood 
units and more total units. The various 
blood loss-related parameters calculated 
for the groups are shown in Table 4. In-
traoperative and total blood loss per fu-
sion level was signifi cantly lower in the 
aprotinin group than in patients receiving 
tranexamic acid. There were no differenc-
Table 1
Surgery Characteristics
APT (n30) TXA (n39)
P valueMean SD Mean SD
Duration of the surgical 
intervention (min)
662.3 210.6 448.4 157.2 .001
No of levels fused 11.2 4.3 7.6 5.8 .004
Days of hospitalization 17.2 10.3 13.2 8.8 .086
Abbreviations: APT, aprotinin; TXA, tranexamic acid.
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es between the groups in the intraoperative 
blood loss per hour of surgery, transfused 
units per hour of surgery nor transfused 
units per level fused.
The fi rst multivariate analysis identi-
fi ed sex (P.005), age (P.001) and sur-
gery duration (P.001) as independent 
variables related with blood loss in spine 
surgery. Type of antifi brinolytic was not 
statistically signifi cant (P.07). Accord-
ing to the multivariate model, the variable 
surgery duration was the clearly the main 
predictive factor of total blood loss among 
the patients in our study. The geometric 
mean of the variable total blood loss (ie, 
the mean adjusted by age, sex, and dura-
tion of surgery) was 2478 mL for the apro-
tinin group and 2972 for the tranexamic 
acid group, Blood loss was 16.4% lower 
(95% CI , 2.1%-32%) in patients receiv-
ing aprotinin as compared to those receiv-
ing tranexamic acid, although the differ-
ence was not statistically signifi cant.
In the second multivariate model, the 
variables signifi cantly associated with 
the number of transfused units were 
age (P.013) and duration of surgery 
(P.001). Again, the type of antifi brinol-
ytic given was not signifi cant (P.4). The 
geometric means were 2.85 for the apro-
tinin group and 3.26 for those receiving 
tranexamic acid, which represents a rela-
tive transfusion reduction of 12.6% (95% 
CI, 21.2%-36.9%) in the aprotinin group. 
None of the patients in either group ex-
perienced complications related with the 
administration of antifi brinolytic drugs 
including thromboembolic events, renal 
insuffi ciency, cardiac complications or 
anaphylactic phenomena.
DISCUSSION
Blood loss is one of the most important 
complications associated with complex 
surgery of the spine and has been attribut-
ed to the duration of surgery, among other 
factors.6,16-18 Our results provide further 
support that the length of the intervention 
is a predictive variable for perioperative 
blood loss. Other predictive factors found 
Table 2
Blood Loss
APT (n30) TXA (n39)
P valueMean SD Mean SD
Preoperative hemo-
globin (g/dL)
12.5 1.6 13.0 1.7 .165
Preoperative hema-
tocrit (%)
36.5 4.4 38.1 4.8 .161
Intraoperative blood 
loss (mL)
2118.3 1255.8 1608.7 1012.8 .066
Postoperative blood 
loss (mL)
1227.2 623.5 1017.2 776.8 .230
Total blood loss (mL) 3312.2 1523.9 2627.2 1386.3 .056
Postoperative hemo-
globin (g/dL)
9.9 1.1 10.3 1.1 .236
Postoperative hema-
tocrit (%)
29.9 3.4 29.8 3.0 .900
Abbreviations: APT, aprotinin; TXA, tranexamic acid.
Table 3
Blood Units Transfused
APT TXA P value
Patients 30 39
Total no. units 
transfused
4.12.1 2.62.2 .008
Autologous units 
transfused
2.22.1 1.31.5 .047
Allogeneic units 
transfused
1.82.6 1.32.3 .37
Abbreviations: APT, aprotinin; TXA, tranexamic acid.
Table 4
Various Ratios Related With Blood Loss 
Ratio APT TXA P value
Intraoperative blood loss/no. of 
fused levels (mL per level)
228.5 ± 187.5 428.1 ± 494.7 .025
Intraoperative blood loss/ dura-
tion surgical intervention (mL 
per hour surgery)
192.5 ± 81.6 216.7 ± 118.9 .3
Transfusion units / duration 
surgical intervention (mL per 
hour surgery)
0.34 ± 0.75 0.38 ± 0.36 .4
Transfusion units / no. of fused 
levels (mL per level)
0.43 ± 0.26 0.53 ± 0.75 .4
Abbreviations: APT, aprotinin; TXA, tranexamic acid.
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in this study include age (the older the pa-
tient, the greater the blood loss) and sex 
(greater bleeding in males), for which the 
independent impact on blood loss is diffi -
cult to explain. Nevertheless, several vari-
ables that were not included in the study 
design (neuromuscular deformity, osteo-
porosis) may contribute to explaining the 
differences found. 
One of the main objectives in complex 
spine surgery is to reduce the number of 
blood units administered.8,16-19 Again, sur-
gery duration and sex were independent 
predictors of transfusion. In contrast, the 
baseline hemoglobin and hematocrit did 
not emerge as independent predictive fac-
tors, although they are considered major 
predictors in other types of orthopedic 
surgeries.5,20
Our results suggest that aprotinin is 
slightly superior to tranexamic acid in 
reducing blood loss and transfusion re-
quirements in complex spine surgery. 
Nevertheless, we cannot draw fi rm con-
clusions because our study is observa-
tional and groups were different in some 
critical variables such as duration of 
surgery and number of fused levels. The 
aprotinin group included patients with 
conditions that can be labeled “complex 
deformities.” The surgical procedures to 
treat these conditions usually involve in-
strumentation of several levels as well as 
circumferential fusions. The tranexamic 
acid group included patients undergoing 
complex surgery for degenerative lumbo-
sacral disease, some with decompression 
at several levels and PLIF procedures. 
These differences between the treatment 
groups explains why bleeding was higher 
in patients receiving aprotinin (3312 mL) 
as compared to the tranexamic acid group 
(2627 mL). In addition, a signifi cant dif-
ference was  found for the total num-
ber of units transfused (aprotinin 4.1 vs 
tranexamic acid 2.6; P.008).  However, 
the analysis of the parameters blood loss 
per fusion level and blood loss per hour 
of surgery (Table 4) suggests that the dif-
ferences are not attributable to the type of 
treatment received, but instead to the fact 
that the most complex patients (greater 
number of levels fused, lengthier surgery, 
and circumferential approach) had been 
assigned to the aprotinin group. On the 
contrary, analysis of the geometric mean 
(i.e., the mean adjusted by age, sex and du-
ration of surgery) indicates that aprotinin 
use results in a 16.4% greater reduction in 
blood loss and a 12.4% greater decrease 
in the number of blood units transfused as 
compared to tranexamic acid. These data 
suggest that aprotinin administration pro-
duces a comparatively larger reduction in 
operative bleeding and secondarily, a de-
crease in the number of units transfused.
Despite the growing evidence of the 
benefi ts of both aprotinin and tranexamic 
acid for reducing blood loss and transfu-
sion requirements in spine surgery, there 
are no studies comparing these treat-
ments. The introduction of antifi brinolytic 
drugs to control intraoperative bleeding is 
relatively recent in spine surgery. The fi rst 
related studies assessed the effi cacy of 
aprotinin or tranexamic acid against pla-
cebos.7,9,21-23 Urban et al16 reported a com-
parison between aprotinin, epsilon-ami-
nocaproic acid and placebo in a series of 
adult patients with complex scoliosis and 
characteristics similar to the patients in 
the present study. The authors found that 
intraoperative blood loss and transfusion 
requirements were signifi cantly lower in 
patients receiving aprotinin, with no dif-
ferences between the epsilon-aminocapro-
ic acid and placebo groups. Randomized, 
double-blind studies comparing aprotinin 
with a control group and reported by Cole 
et al7 and Khoshhal et al9 have described 
the effi cacy of aprotinin for reducing in-
traoperative blood loss in children and 
adults undergoing surgery for spinal de-
formity. Lentschener et al23 found a signif-
icant decrease in blood loss and number of 
units transfused as compared to a placebo 
group in patients treated with lumbosacral 
fusion. 
Other authors have not found these su-
perior results for aprotinin versus placebo. 
Amar et al24 reported no differences in 
surgical bleeding or transfusion needs in 
a randomized study comparing aprotinin 
and epsilon-aminocaproic acid versus a 
placebo in skeletal surgery for neoplastic 
disease. Nonetheless, the duration of sur-
gery was clearly shorter in these patients 
as compared to the series of Urban et al16 
and our patients.  
Recent meta-analyses have confi rmed 
the effi cacy of tranexamic acid for re-
ducing intraoperative blood loss and 
transfusion requirements in various or-
thopedic procedures performed in adult 
patients,13,25,26 as well as in spine surgery. 
Neilipovitz et al21 found a signifi cant re-
duction in transfusion needs in a prospec-
tive, randomized, controlled study com-
paring tranexamic acid versus placebo 
in children and adolescents undergoing 
scoliosis surgery. Sethna et al22 reported 
a signifi cant decrease in intraoperative 
blood loss, but no difference in transfu-
sion needs, in a randomized controlled 
trial comparing tranexamic acid versus 
placebo in patients undergoing scheduled 
scoliosis correction. 
Our results suggest a small advantage 
of using aprotinin. The meta-analysis of 
Zufferey et al13 also points in this direction. 
However, in an editorial comment on the 
meta-analysis, Wesikopf27 indicated that 
the difference may have little clinical rel-
evance. In ou study, this reduction would 
represent saving 0.48 of transfusión units 
or reducing 529 mL of blood loss.  More-
over, this slight advantage should also be 
assessed in terms of safety and cost. The 
safety of aprotinin use is currently under 
considerable discussion. Recent studies 
assessing the safety of this agent in cardi-
ac surgery28,29 have concluded that the risk 
of death and complications of severe renal 
failure are higher in patients undergoing 
coronary artery bypass graft surgery with 
aprotinin treatment. Another drawback to 
the use of this drug is the risk of severe 
anaphylactic reactions, which have been 
reported at around 4%.30 In contrast, no 
problems related with safety have been 
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described for tranexamic acid. Lastly, al-
though a comparative cost assessment of 
these two treatments is beyond the scope 
of this study, the elevated cost of aprotinin 
relative to tranexamic acid is well recog-
nized. In fact, Kovesi et al31 have noted 
that this factor could be one of the main 
disadvantages for carrying out controlled 
clinical trials comparing these drugs. 
In conclusion, our results show that the 
duration of the surgical procedure is the 
main variable having an impact on opera-
tive bleeding and transfusion requirements 
in complex spine surgery. It is likely that 
aprotinin use results in a greater reduc-
tion in operative bleeding than tranexamic 
acid. Nevertheless, the difference was not 
statistically signifi cant and its clinical rel-
evance does not seem evident.
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